Positions Lifeward as a MedTech platform with a clear path to cashflow positive and long-term Biotech upside potential Up to $47 million strategic investment from Oramed and another investor is intended to provide Lifeward cash runway to profitability and diversify its portfolio across MedTech and BioTech Lifeward acquires Oramed’s clinical-stage Protein Oral Delivery (POD™) technology adding exposure to a large, long-term Biotech market opportunity POD™ targets the $600+ billion injectable drugs market, i ...

With a market cap of $18.4 billion, Indiana-based Zimmer Biomet Holdings, Inc. (ZBH) is a global medical technology leader specializing in musculoskeletal healthcare. The company designs, manufactures, and markets a broad portfolio of orthopedic reconstructive implants, sports medicine and trauma products, dental solutions, and surgical technologies, including robotic-assisted systems. The company is slated to announce its fiscal Q4 2025 results soon. Ahead of the event, analysts expect Zimmer Biomet to ...

Core Viewpoint - Terumo, a Japanese medtech company, emphasizes the importance of quality in medical devices, particularly in vascular access, highlighting its guidewire as a gold standard in the industry [2][3][4]. Group 1: Company Overview - Terumo is represented by CEO Hikaru Samejima at the JPMorgan Healthcare Conference, marking a significant opportunity for the company to present its vision and innovations [2]. - The company has a long-standing history, with its guidewire being used in the largest number of procedures over the past 40 years, underscoring its reliability and impact on patient recovery [3]. Group 2: Product Significance - The guidewire, while appearing as a simple product, plays a crucial role in medical procedures, significantly influencing patient outcomes [3]. - Terumo's commitment to quality ensures that its medical devices are reliable and effective in daily medical settings, which is essential for patient safety [4].

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Terumo (OTCPK:TRUM.Y) FY Conference January 12, 2026 08:15 PM ET Company ParticipantsJin Hagimoto - CFOHikaru Samejima - CEOConference Call ParticipantsNone - AnalystOperatorGood evening. Thank you for joining us. I'm Naoki Sato from J.P. Morgan. Welcome to J.P. Morgan Healthcare Conference, Terumo's presentation. Again, it's my pleasure to be introducing Terumo. From the company, we have CEO Hikaru Samejima for the presentation, and after that, we'll have a Q&A session. With that, I will pass on to Mr. Sam ...

Core Viewpoint - Baxter is undergoing a leadership transition with Andrew Hider as the new CEO, emphasizing continuous improvement and operational excellence as key components of the company's strategy [2][3]. Company Overview - Baxter is recognized as an iconic brand in the medical technology sector, aiming to deliver high value to its customers [3]. - The company has significant opportunities for improvement and growth in various areas [3]. Leadership Background - Andrew Hider has a diverse background in the industry, having worked at General Electric and Danaher Corporation, where he managed multiple companies across different sectors [2]. - Hider has been with Baxter for five months and is focused on leveraging his experience to enhance the company's operations [2].

J.P. Morgan Healthcare Conference 2026 Hikaru Samejima Chief Executive Officer Terumo Corporation Jan. 12, 2026 Forward-Looking Statements and Use of Document Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projection ...

2026 JP Morgan Healthcare Conference Damien McDonald Chief Executive Officer Ben Berry Chief Financial Officer Kyle Rose Vice President, Investor Relations Presentation Title is set in ALL CAPS Short description is set in sentence case This presentation includes forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Enovis' plans, g ...

PresentationGood morning, everyone. I'm Robbie Marcus, the Med Tech Analyst at JPMorgan. Very happy to introduce our next company, CeriBell. We'll have Jane Chao, the CEO, come up for a presentation followed by some Q&A. Jane?Xingjuan ChaoCo-Founder, President, CEO & Director Thank you, Robbie. Good morning, everyone. I'm very excited to share with you the overview of CeriBell and our 2025 accomplishment and 2026 plan. So at the highest level, CeriBell has developed a platform for neuromonitoring. It has th ...

PresentationGood afternoon, everyone. I hope you enjoyed your lunch. I'm Robbie Marcus, the med tech analyst at JPMorgan. Very happy to present our next speaker, Brent Saunders, the CEO of Bausch + Lomb. Brent will do a presentation followed by some Q&A. Brent?Brenton L. SaundersCEO & Chairman Good afternoon, and thank you for joining us here today. The JPMorgan Healthcare Conference brings together companies that are not only competing in health care, but shaping where the industry is going and we're very ...